Abstract:Background: High HIV viral loads (VL) are associated with increased morbidity, mortality, and on-going transmission. HIV controllers maintain low VLs in the absence of antiretroviral therapy (ART). We previously used a massively multiplexed antibody profiling assay (VirScan) to compare antibody profiles in HIV controllers and persons living with HIV (PWH) who were virally suppressed on ART. In this report, we used VirScan to evaluate whether antibody reactivity to specific HIV targets and broad reactivity across the HIV genome was associated with VL and controller status 1-2 years after infection. Methods: Samples were obtained from participants who acquired HIV infection in a community-randomized trial in Africa that evaluated an integrated strategy for HIV prevention (HPTN 071 PopART). Controller status was determined using VL and antiretroviral (ARV) drug data obtained at the seroconversion visit and 1 year later. Viremic controllers had VLs <2,000 copies/mL at both visits; non-controllers had VLs >2,000 copies/mL at both visits. Both groups had no ARV drugs detected at either visit. VirScan testing was performed at the second HIV-positive visit (1-2 years after HIV infection). Results: The study cohort included 13 viremic controllers and 64 non-controllers. We identified ten clusters of homologous peptides that had high levels of antibody reactivity (three in gag, three in env, two in integrase, one in protease, and one in vpu). Reactivity to 43 peptides (eight unique epitopes) in six of these clusters was associated with lower VL; reactivity to six of the eight epitopes was associated with HIV controller status. Higher aggregate antibody reactivity across the eight epitopes (more epitopes targeted, higher mean reactivity across all epitopes) and across the HIV genome was also associated with lower VL and controller status. Conclusions: We identified HIV antibody targets associated with lower VL and HIV controller status 1-2 years after infection. Robust aggregate responses to these targets and broad antibody reactivity across the HIV genome were also associated with lower VL and controller status. These findings provide novel insights into the relationship between humoral immunity and viral containment that could help inform the design of antibody-based approaches for reducing HIV VL.

Public T cell clonotypes are selected in HLA-B∗57:01+/HIV+ patients independently of the viral load

T cell receptors for the HIV KK10 epitope from patients with differential immunologic control are functionally indistinguishable.

Association of HLA-DRB1-restricted CD4⁺ T cell responses with HIV immune control.

Structural Basis for Unusual TCR CDR3β Usage Against an Immunodominant HIV-1 Gag Protein Peptide Restricted to an HLA-B*81:01 Molecule

Structural Basis for Unusual TCR CDR3 beta Usage Against an Immunodominant HIV-1 Gag Protein Peptide Restricted to an HLA-B*81:01 Molecule

Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry

Polymorphic residues in HLA-B that mediate HIV control distinctly modulate peptide interactions with both TCR and KIR molecules

Cross-reactive TCR with Alloreactivity for Immunodominant HIV-1 Epitope Gag TL9 with Enhanced Control of Viral Infection

Impact of HLA class I functional divergence on HIV control

Molecular basis of differential HLA class I-restricted T cell recognition of a highly networked HIV peptide

HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression

Structural Basis of the TCR-pHLA Complex Provides Insights into the Unconventional Recognition of CDR3β in TCR Cross-Reactivity and Alloreactivity

Transcriptional Profiling of CD4 T Cells Identifies Distinct Subgroups of HIV-1 Elite Controllers

Recognition patterns of HLA-A2-restricted human immunodeficiency virus-1-specific cytotoxic T-lymphocytes in a cohort of HIV-1-infected individuals

Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads

Identification of antibody targets associated with lower HIV viral load and viremic control

Heterogeneous Neutralizing Antibody and Anti Body-Dependent Cell Cytotoxicity Responses in Hiv-1 Elite Controllers

Potential role for HIV-specific CD38-/HLA-DR+ CD8+ T cells in viral suppression and cytotoxicity in HIV controllers

Preferential CTL targeting of Gag is associated with relative viral control in long-term surviving HIV-1 infected former plasma donors from China

Cd4(+) T Cells from Elite Controllers Resist Hiv-1 Infection by Selective Upregulation of P21

Influence of HLA-C expression level on HIV control.